Washington University School of Medicine

Digital Commons@Becker
Open Access Publications
2006

Bypassing complement: Evolutionary lessons and future
implications
John P. Atkinson
Washington University School of Medicine in St. Louis

Michael M. Frank
Duke University Medical Center

Follow this and additional works at: https://digitalcommons.wustl.edu/open_access_pubs

Recommended Citation
Atkinson, John P. and Frank, Michael M., ,"Bypassing complement: Evolutionary lessons and future
implications." The Journal of Clinical Investigation. 116,5. 1215-1218. (2006).
https://digitalcommons.wustl.edu/open_access_pubs/1559

This Open Access Publication is brought to you for free and open access by Digital Commons@Becker. It has been
accepted for inclusion in Open Access Publications by an authorized administrator of Digital Commons@Becker.
For more information, please contact vanam@wustl.edu.

Downloaded on August 5, 2013. The Journal of Clinical Investigation. More information at www.jci.org/articles/view/28622

commentaries
14. Pauza, M.E., et al. 2004. T-cell receptor transgenic
response to an endogenous polymorphic autoantigen determines susceptibility to diabetes. Diabetes.
53:978–988.
15. Lieberman, S.M., and DiLorenzo, T.P. 2003. A comprehensive guide to antibody and T-cell responses
in type 1 diabetes. Tissue Antigens. 62:359–377.
16. Moriyama, H., et al. 2003. Evidence for a primary
islet autoantigen (preproinsulin 1) for insulitis and
diabetes in the nonobese diabetic mouse. Proc. Natl.
Acad. Sci. U. S. A. 100:10376–10381.
17. Thebault-Baumont, K., et al. 2003. Acceleration of
type 1 diabetes mellitus in proinsulin 2-deficient
NOD mice. J. Clin. Invest. 111:851–857. doi:10.1172/
JCI200316584.
18. Jaeckel, E., Lipes, M.A., and von Boehmer, H. 2004.
Recessive tolerance to preproinsulin 2 reduces but
does not abolish type 1 diabetes. Nat. Immunol.
5:1028–1035.
19. Kubosaki, A., et al. 2004. Targeted disruption of
the IA-2beta gene causes glucose intolerance and
impairs insulin secretion but does not prevent the

development of diabetes in NOD mice. Diabetes.
53:1684–1691.
20. Kubosaki, A., Miura, J., and Notkins, A.L. 2004. IA2 is not required for the development of diabetes in
NOD mice. Diabetologia. 47:149–150.
21. Lieberman, S.M., et al. 2003. Identification of the
beta cell antigen targeted by a prevalent population
of pathogenic CD8+ T cells in autoimmune diabetes. Proc. Natl. Acad. Sci. U. S. A. 100:8384–8388.
22. Robles, D.T., et al. 2002. Millennium award recipient contribution. Identification of children with
early onset and high incidence of anti-islet autoantibodies. Clin. Immunol. 102:217–224.
23. Redondo, M.J., et al. 2000. DR and DQ associated
protection from type 1 diabetes: comparison of
DRB1*1401 and DQA1*0102-DQB1*0602. J. Clin.
Endocrinol. Metab. 85:3793–3797.
24. Valdes, A.M., et al. 2005. D6S265*15 marks a
DRB1*15, DQB1*0602 haplotype associated with
attenuated protection from type 1 diabetes mellitus. Diabetologia. 48:2540–2543.
25. Kent, S.C., et al. 2005. Expanded T cells from pan-

creatic lymph nodes of type 1 diabetic subjects recognize an insulin epitope. Nature. 435:224–228.
26. Chen, Z., Benoist, C., and Mathis, D. 2005. How
defects in central tolerance impinge on a deficiency in regulatory T cells. Proc. Natl. Acad. Sci. U. S. A.
102:14735–14740.
27. Vieira, P.L., et al. 2004. IL-10-secreting regulatory T cells do not express Foxp3 but have comparable regulatory function to naturally occurring CD4+CD25+ regulatory T cells. J. Immunol.
172:5986–5993.
28. Eisenbarth, G.S. 2005. Prediction of type 1 diabetes: the natural history of the prediabetic period.
In Type 1 diabetes: molecular, cellular and clinical
immunology. Barbara Davis Center for Childhood
Diabetes. http://www.uchsc.edu/misc/diabetes/
oxch11.html.
29. Roep, B.O., et al. 1999. Autoreactive T cell responses in insulin-dependent (type 1) diabetes mellitus.
Report of the first international workshop for
standardization of T cell assays. J. Autoimmun.
13:267–282.

Bypassing complement: evolutionary lessons
and future implications
John P. Atkinson1 and Michael M. Frank2
1Department

of Medicine, Division of Rheumatology, Washington University School of Medicine, St. Louis, Missouri, USA.
of Pediatrics, Immunology and Medicine, Duke University Medical Center, Durham, North Carolina, USA.

2Department

Lectins like mannan-binding protein are part of the innate immune system.
They circulate in association with serine proteases. Upon binding oligosaccharides, they activate the complement cascade analogous to the more familiar but evolutionarily more recent classical pathway, which is triggered by
antibody binding to antigen. In this issue of the JCI, Selander et al. developed a sensitive and specific ELISA employing Salmonella-specific sugars to
assess the activity of the lectin pathway of complement activation (see the
related article beginning on page 1425). This more physiologic assay system
allowed the investigators to rigorously define the requirements for lectin
pathway activation. Furthermore, they uncovered an unsuspected means for
this pathway to reach the desired critical step of activation of the opsonin
C3. These types of functional assays will eventually replace the more laborious, less physiologic, and less informative approaches currently in use to
monitor complement activation.
Innate immunity suffices for most organisms on this planet. Antibodies and lymphocytes did not appear on the evolutionary scene until cartilaginous fish and
sharks. The complement system is a major
player in this innate immunity. The initial
half of this proteolytic complement cascade accomplishes 2 goals: first, to deposit
opsonic fragments derived from compleNonstandard abbreviations used: MASP, MBL-associated serine protease; MBL, mannan-binding lectin.
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ment components 3 and 4 (C3 and C4,
respectively) on a target, and second, to initiate the inflammatory response through
release of the C3a anaphylatoxin. These 2
events occur in parallel and within minutes, making complement activation an
early (if not the earliest) part of the host
defense response to a microbe. Three activation pathways — classical (Figure 1),
lectin (Figure 2), and alternative (Figure 3)
— have been elucidated. They join at the
step of C3 cleavage. Common to each pathway is the terminal half of the system, the
membrane attack complex. This lytic system is initiated with the cleavage of C5 to
C5a, another potent anaphylatoxin, and
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C5b, which combines with C6, C7, C8, and
C9 to form a pore or channel in the pathogen’s cell membrane. Deficiencies in complement components predispose to infection and autoimmunity. While it is rather
straightforward to account for the former,
it has not been so easy for immunologists
to explain the latter.
The complement system is activated by
lectins, representing a preantibody means
of recognizing non-self by targeting the
distinct sugar profiles of microorganisms (Figure 2). Not surprisingly, parts of
the lectin complement cascade were then
“borrowed” by the adaptive immune system to form the antibody-triggered classi-

Figure 1
Three pathways of complement activation.
Deposition of clusters of C3b on a target is
the primary goal. The alternative pathway also
serves as a feedback loop such that C3b deposition can be amplified (shown by broken line).
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Figure 2
Lectin pathway. This pathway, also called the
MBL pathway, is activated by the binding of
MBL and other lectins to sugar moieties on the
surface of pathogens, which results in cleavage of C4 and C2 to produce the C3 convertase C4b2a. The convertase that is formed is
the same as that in the classical pathway of
complement activation.

cal pathway. Complement also undergoes
a continuous turnover of its key component, C3, which is the initiating event for
the alternative pathway (Figure 3). Spontaneous turnover of C3 continuously generates C3b, allowing the alternative pathway
to function independently of the classical
or lectin pathways. This initial C3b can
also be generated via the classical or lectin
pathways. On cells lacking complement
inhibitors, the deposited C3 fragment C3b
is the nidus for amplification via the alternative pathway.
Evolution of the complement system
The complement system is an ancient host
defense pathway. As organisms became
complex, the system evolved to be more
efficient. The most primitive complement system probably initially consisted

primarily of C3. C3 (and C4) possesses a
biochemical mechanism whereby a fluidphase protein may transfer to a surface.
Specifically, cleavage of C3 exposes a highly
reactive thioester bond that mediates covalent attachment to hydroxyl groups on cell
surfaces. Once C3b is covalently bound to
a pathogen, the alternative pathway’s feedback loop becomes engaged (Figure 3). The
end result of this amplification process is
deposition of large amounts of C3b, which
opsonize the pathogen, and the concomitant liberation of the proinflammatory
C3a anaphylatoxin.
However, this early complement system
lacks a more specific means to identify
appropriate targets. This void was apparently first filled with lectins such as mannan-binding lectin (MBL) or mannan-binding protein. Lectins bind repeating sugar

moieties on pathogens and then activate
complement by engaging MBL-associated serine proteases (MASPs) (Figure 2).
Initially, these serine proteases may have
directly cleaved and thereby activated C3.
To make the lectin pathway of complement
activation more efficient, an intermediate step employing C4 and C2 developed.
Together they form an enzyme complex —
C4b2a — that efficiently cleaves C3 to C3b
(Figure 2). The void was next filled with the
highly successful humoral immune system
in which the complement activating agent
antibody defines the target.
Discovery of bypass pathways
Many fits and starts and reformulations
undoubtedly occurred during the evolution of the complement system. These less
evolved cascades, though, are difficult to

Figure 3
Feedback loop of the alternative pathway. C3b is formed by spontaneous C3 turnover in blood or generated by the lectin or classical pathways.
C3b bound to a substrate binds the serine protease factor B (B). This low-affinity complex is converted by the serine protease factor D (D) to a
C3-cleaving enzyme, C3bBb. This enzyme complex is stabilized by properdin (P). C3bBbP then cleaves C3 to C3a and C3b to complete the
loop and lead to amplification.
1216
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Figure 4
Lectin pathway in normal versus C2-deficient serum. In this issue of the JCI, Selander
et al. (7) examined the mechanism of complement activation by MBL in the setting of C2
deficiency. Lectins bind sugar moieties on target pathogens and subsequently activate
complement via MASPs. In normal human sera, MASPs cleave C4 and C2 to form the
C3 convertase C4b2a. Surprisingly, Selander et al. found that in human sera from individuals deficient in C4 or C2, MBL is still capable of inducing substantial C3 deposition
by engagement of the alternative pathway and formation of the C3 convertase C3bBb.
This bypass pathway may be functioning in individuals with acquired or naturally occurring complement deficiencies.

recognize. An obvious approach to uncover
these earlier renditions of the complement
system is to characterize the system in
lower species. This is not so easy to achieve
experimentally, however, especially in nonvertebrates, because there are over 30 distinct interacting components, receptors,
and regulators to consider. A second window to evolutionary history is provided by
the assessment of individuals with complement component deficiencies. Thus the
first such bypass system to come to light
was identified by researchers at the NIH
employing C4-deficient guinea pig serum
(1–3). Although they require higher quantities of sensitizing IgG or IgM than the traditional classical pathway, sheep red blood
indicator cells were lysed in this serum.
This C4 bypass pathway also required a C1like protein and the alternative pathway. At
this juncture the lectin pathway had not
yet been discovered, so the C1-like protein
complex could have been a MASP. The NIH
group further demonstrated that C2-deficient human serum could lyse cells under
similar conditions (1–3). In other words,
C4 and C2 were not necessary to lyse cells
by the classical pathway.
These bypass pathways were next analyzed by Matsushita and Okada, who
showed that C4b deposited on cells could
facilitate alternative pathway activation in
human serum lacking C2 (4). Further work
on these pathways also came about because
of a serendipitous observation: a patient
with complete C2 deficiency and systemic
lupus erythematosus was reported by the
clinical laboratory to have a total hemolytic complement titer approximately 50%
of normal (5). As C2 is required for classical
pathway activation, on multiple occasions

the titer in this patient had been measured
as zero. Upon further analysis, it turned
out that during this recent assay, approximately 10 times the usual amount of sensitizing antibody had been employed (5, 6).
While the total hemolytic complement titer
of control (normal) serum was unchanged
in the setting of these more heavily sensitized cells, serum of a C2-deficient individual was able to activate the cascade.
The biochemical process that permitted
this bypass pathway to be engaged was not
through a hybrid classical pathway/alternative pathway convertase (4, 6). Instead,
the formation of the alternative pathway
was facilitated, probably by providing a site
relatively protected from regulators.
Improved assay systems to monitor
complement activation
Traditionally it has been thought that lectins activate complement through a C4and C2-dependent pathway analogous to
the classical pathway. In this issue of the
JCI, Selander et al. examined the requirements for mannan-binding protein activation of the lectin pathway (7). Of note, they
employed sensitive ELISA methodology in
which the lectins in the test serum bound
to the O oligosaccharides of several Salmonella species. The readout was the quantitation of C3 deposition on the plate. Important features of their assay system as well
as similar ones developed by others (8) are
specificity for a given pathway, greater sensitivity, and use of actual pathogen material as substrates. Also, the concentrations of
serum employed more closely match those
in body secretions and blood. These types
of assays will eventually become standard
in the clinical immunology laboratory.
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They provide a functional assessment, are
easier to perform, and delineate more precisely and in a more physiologic manner the
complement pathway(s) being activated.
They will replace the current total hemolytic complement test. The widely available
total hemolytic complement assay measures only the classical pathway and uses
highly diluted serum and a sheep red blood
cell target — none of which closely approximate the complement system interacting
with a microbe in vivo.
Using an improved assay system, Selander et al. (7) demonstrate that even in the
absence of C2, C4, or a MASP, mannanbinding protein induces substantial C3
deposition. Analogous to the results noted
above relative to bypass systems in the classical cascade, these results point to a new
pathway by which lectins may activate the
complement pathway (Figure 4). Although
this likely is not a major pathway of complement activation, it may be operative in
the context of either acquired or naturally
occurring complement deficiencies.
Implications
Why is this the study by Selander et al. (7)
important? The primary finding is the demonstration that individuals deficient in C4
or C2 possess a “backup” or bypass complement activation system. Second, the study
reaffirms the likely evolutionary history of
the complement system. Third, these bypass
pathways can mediate immunopathology.
For example, the lysis of Giardia lamblia trophozoites (9), tissue damage in Forssman
shock (10), binding of immune complexes
to complement receptors (11, 12), and
endothelial cell damage in hemolytic uremic syndrome (13) can all be shown to be
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mediated by complement bypass systems.
Fourth, and probably most important, the
type of assay represents the wave of the
future in detecting the activity of the complement system in human disease. As these
more informative detection systems (like the
one used in this report) come into routine
clinical use, other examples of these bypass
type pathways will likely be uncovered. For
human diseases, these more specific and
quantitative assay systems will establish
which pathway of complement activation is
playing a role in disease and elucidate which
one to modulate with therapeutic agents.
Finally, a word of caution is in order. These
bypass pathways are often not considered
by investigators attempting to define the
role of the complement system in disease
states. For example, C4-deficient animals
are widely used to rule out a contribution of
the classical pathway and/or lectin pathway
in mouse models of human disease. One
must be wary of such interpretations in
view of bypass cascades that become operative in “deficient” states. Thus the natural
maturation of an antibody response to an
infectious organism (i.e., to go rapidly into
antibody excess) is all that is necessary to

trigger these more ancient bypass pathways.
Using our current methods, such pathways
are not analyzed in clinical medicine or in
animal models of human disease.
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The IL-23/IL-17 axis in inflammation
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IL-23 induces the differentiation of naive CD4+ T cells into highly pathogenic helper T cells (Th17/ThIL-17) that produce IL-17, IL-17F, IL-6, and TNF-α,
but not IFN-γ and IL-4. Two studies in this issue of the JCI demonstrate that
blocking IL-23 or its downstream factors IL-17 and IL-6, but not the IL-12/
IFN-γ pathways, can significantly suppress disease development in animal
models of inflammatory bowel disease and MS (see the related articles beginning on pages 1310 and 1317). These studies suggest that the IL-23/IL-17
pathway may be a novel therapeutic target for the treatment of chronic
inflammatory diseases.
Th17/ThIL-17 is a new CD4+ helper
T cell subset that produces IL-17
Upon antigenic stimulation, naive CD4+
T cells differentiate into 2 subsets, Th1
and Th2 cells, characterized by different
cytokine production profiles and effector
Nonstandard abbreviations used: CIA, collageninduced arthritis; IBD, inflammatory bowel disease;
IL-1Ra, IL-1 receptor antagonist; R, receptor.
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functions (Figure 1). Th1 cells produce
large quantities of IFN-γ and mediate cellular immunity while Th2 cells, which are
involved in humoral immunity, primarily produce IL-4, IL-5, and IL-13. IL-12, a
heterodimer of the p40 and p35 subunits,
induces the differentiation of naive CD4+
T cells into IFN-γ–producing Th1 cells
through activation of STAT4. IFN-γ signals
are transduced by STAT1, which activates
a downstream transcription factor, T-bet,
that enhances the expression of genes specific to Th1 cells. In contrast, IL-4 induces
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STAT6 activation, promoting the expression of GATA-3, a transcriptional factor
essential for both IL-4 production and Th2
cell differentiation. Recently, it was reported that CD4 + T cells isolated from the
inflamed joints of patients with Lyme disease contain a subset of IL-17–producing
CD4+ T cells that are distinct from those
producing either IL-4 or IFN-γ (Figure 1)
(1). These IL-17–producing CD4+ T cells
were dubbed Th17 or ThIL-17 cells (2–4).
IL-17, a proinflammatory cytokine predominantly produced by activated T cells,
enhances T cell priming and stimulates
fibroblasts, endothelial cells, macrophages,
and epithelial cells to produce multiple proinflammatory mediators, including IL-1,
IL-6, TNF-α, NOS-2, metalloproteases, and chemokines, resulting in the
induction of inflammation (5, 6). IL-17
expression is increased in patients with
a variety of allergic and autoimmune
diseases, such as RA, MS, inflamma-
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